Proton pump inhibitor (PPI) use has been associated with microbiota alterations and susceptibility 2 to Clostridioides difficile infections (CDIs) in humans. We assessed how PPI treatment alters the 3 fecal microbiota and whether treatment promotes CDIs in a mouse model. Mice receiving a PPI 4 treatment were gavaged with 40 mg/kg of omeprazole during a 7-day pretreatment phase, the day 5 of C. difficile challenge, and the following 9 days. We found that mice treated with omeprazole were 6 not colonized by C. difficile. When omeprazole treatment was combined with a single clindamycin 7 treatment, one cage of mice remained resistant to C. difficile colonization, while the other cage 8 was colonized. Treating mice with only clindamycin followed by challenge resulted in C. difficile 9 colonization. 16S rRNA gene sequencing analysis revealed that omeprazole had minimal impact 10 on the structure of the murine microbiota throughout the 16 days of omeprazole exposure. These 11 results suggest omeprazole treatment alone is not sufficient to disrupt microbiota resistance to C. 12 difficile infection in mice that are normally resistant in the absence of antibiotic treatment. 13 Importance 14
and CDIs seen in humans or whether aspects of murine physiology may limit its utility to test these 23 types of hypotheses. 24 2 Antibiotics have a large impact on the intestinal microbiome and are a primary risk factor for 25 developing Clostridioides difficile infections (CDIs) (1) . It is less clear whether other human 26 medications that impact the microbiota also influence C. difficile colonization resistance. Multiple 27 epidemiological studies have suggested an association between proton pump inhibitor (PPI) use 28 and incidence or recurrence of CDIs (2-5). There have also been a number of large cohort 29 studies and interventional clinical trials that demonstrated specific alterations in the intestinal 30 microbiome were associated with PPI use (4, 6). PPI-associated microbiota changes have been 31 attributed to the ability of PPIs to increase stomach acid pH which may promote the survival of 32 oral and pathogenic bacteria (4, 6). In human fecal samples, PPI use results in increases in 33 Enterococcaceae, Lactobacillaceae, Micrococcaceae, Staphylococcaceae and Streptococcaceae 34 and decreases in Ruminococcaceae (6-9). Several of these taxa have also been associated with 35 C. difficile colonization in humans (10). 36 Unfortunately, the studies suggesting a link between PPIs and C. difficile were retrospective and 37 did not evaluate changes in the microbiome (2, 3, 5). Thus, it is unclear whether the gastrointestinal 38 microbiome changes associated with PPI use explain the association between PPIs and CDIs. 39 Additionally, epidemiological studies have a limited capacity to address potential confounders and 40 comorbidities in patients that were on PPIs and developed CDIs or recurrent CDIs (2, 5). Here, 41 we evaluated the impact of daily PPI treatment with omeprazole on the murine microbiome and 42 susceptibility to C. difficile colonization in relation to clindamycin, an antibiotic that perturbs the 43 microbiome enough to allow C. difficile to colonize but is mild enough that C. difficile is cleared 44 within 10 days (11).
45
Murine fecal microbiomes were minimally affected by omeprazole treatment. To test whether 46 omeprazole treatment alters the microbiome and promotes susceptibility to CDIs, we gavaged 47 mice with 40 mg/kg of omeprazole for 7 days before C. difficile challenge ( Figure 1A) . A principle 48 coordinates analysis (PCoA) of the Bray-Curtis distances over the initial 7 days of treatment revealed 49 the bacterial communities of omeprazole-treated mice remained relatively unchanged ( Figure 1B ). 50 We observed no significant changes in the relative abundance of those taxa previously shown to 51 respond to PPI treatment throughout the course of the 16-day experiment ( Figure 1C -D, S1). We 52 also observed no significant changes in relative abundances at the family and genus level over the 53 3 course of the experiment for the omeprazole-treated mice (all corrected P-values > 0.36). These 54 results demonstrated that the omeprazole treatment alone had a minimal impact on the murine 55 fecal bacterial community after 7 days of pretreatment.
56
Omeprazole treatment did not promote susceptibility to C. difficile infection in mice. Next, 57 we examined whether omeprazole treatment altered susceptibility to C. difficile infection in mice. 58 After omeprazole treatment or clindamycin treatment, mice were challenged with 10 3 C. difficile 59 630 spores. Although C. difficile colonized the clindamycin-treated mice, it did not colonize 60 the omeprazole-treated mice (Figure 2A ). Interestingly, only 1 cage of mice that received both 61 omeprazole and clindamycin were colonized, while the other cage of mice were resistant ( Figure   62 2A). The greatest shifts in bacterial communities occurred in the clindamycin-treated mice ( Figure   63 2B, S2). Regardless of whether the mice became colonized, all of the mice had cleared C. difficile 64 within 5 days (Figure 2A ), suggesting that omeprazole did not affect the rate of clearance. Our 65 results suggest that omeprazole treatment had no effect on bacterial community resistance to 66 C. difficile colonization in mice. Instead most of the differences between the 3 treatment groups 67 appeared to be driven by clindamycin administration (Figure 2C , S2). These findings demonstrated 68 that high dose omeprazole treatment did not promote susceptibility to C. difficile colonization.
69
Conclusions. The PPI omeprazole did not meaningfully impact the structure of the gut microbiota 70 and did not promote C. difficile infection in mice. Our findings that omeprazole treatment had minimal 71 impact on the fecal microbiome were comparable to another PPI mouse study that indicated the 72 PPI lansoprazole had more of an effect on the small intestinal microbiota compared to the fecal 73 microbiota (12). The same group demonstrated lansoprazole treatment increased the stomach 74 pH in mice (12), which may improve survival of bacteria passing through the stomach. We did 75 not find significant changes in the relative abundances of the taxa observed to be significantly 76 impacted by PPI use in human studies. However, 3 of the human-associated taxa were absent or 77 at low abundance in our mice. Interestingly, other groups examining fecal microbiota communities 78 before and after PPI administration to healthy cats and infants with gastroesophageal reflux disease, 79 found PPIs have minimal effects on fecal bacterial community structures, although there were a 80 few significant changes in specific genera (13, 14) . One limitation of our study is that there were 81 only 4-5 mice per group, which may have limited our ability to identify PPI-induced changes in 82 4 specific bacteria genera. Although our fecal microbiota findings are comparable to what has been 83 shown in another mouse study (12), whether PPI-induced changes in specific bacterial abundances 84 observed in humans play a role in CDIs remains to be determined. 85 Although several C. difficile mouse model studies have shown that PPIs have an effect on CDIs 86 with or without additional antibiotic treatment (15-17), there were insufficient controls to attribute 87 the effect solely to PPI treatment. One group administered 0.5 mg/kg of the PPI lansoprazole daily 88 for 2 weeks to mice and then challenged with C. difficile demonstrated that PPI treatment alone 89 resulted in detectable C. difficile in the stool 1 week after challenge, however there was detectable 90 C. difficile in mice not treated with antibiotics (15, 16). The other mouse study demonstrated 91 antibiotic/esomeprazole-treated mice developed more severe CDIs compared to antibiotic-treated 92 mice, but the researchers did not have a group treated with just esomeprazole for comparison 93 (17). We tested the same high 40 mg/kg PPI dose and expanded pre-treatment to 7 days before 94 challenge to test the impact of omeprazole treatment alone on our CDI mouse model. Additionally, 95 we have previously demonstrated that mice from our breeding colony are resistant to C. difficile 630 96 colonization without antibiotic treatment (18), ensuring there was not already partial susceptibility 97 to C. difficile before treatment. The additional controls in our study allowed us to assess the 98 contribution of omeprazole alone to C. difficile susceptibility in mice. 99 Our study also extended previous work examining PPIs and C. difficile in mice by incorporating the 100 contribution of the intestinal microbiota. We found omeprazole had no significant impact on bacterial 101 taxa within the murine intestinal microbiota over the 16-day experiment. In contrast to previous 102 work with PPIs (15-17), omeprazole did not alter C. difficile colonization resistance in mice. 16S 103 rRNA sequencing suggested that Streptococcus and Enterococcus are rare genera in our C57BL/6 104 mouse colony. These two genera could be important contributors to the associations between PPIs 105 and CDIs in humans, and could be a contributing factor to our observation that PPI treatment had 106 no effect on C. difficile colonization in our CDI mouse model. While the intestinal microbiomes 107 of both humans and mice are dominated by the Bacteroidetes and Firmicutes phyla, there are 108 significant differences in the relative abundances of genera that are present and some genera 109 are unique to each mammal (19), differences that may partly explain our results. Gastrointestinal 110 physiological differences, particularly the higher stomach pH in mice (pH 3-4) compared to humans 111 (pH 1) (19) could also explain why omeprazole had a limited impact on the murine microbiome. The 112 5 microbiota and physiological differences between humans and mice may limit the usefulness of 113 employing mouse models to study the impact of PPIs on the microbiota and CDIs. 114 Beyond microbiome differences, factors such as age, body mass index, comorbidities, and use 115 of other medications in human studies may also be contributing to the association between PPIs 116 and CDI incidence or recurrence. The type of C. difficile strain type could also be an important 117 contributing factor, however our study was limited in that we only tested C. difficile 630 (ribotype as described previously (23). In brief, the ZymoBIOMICS TM Microbial Community DNA Standard 159 (Zymo, CA, USA) was used as a mock community (24) and water was used as a negative control. 160 The V4 hypervariable region of the 16S rRNA gene was amplified with Accuprime Pfx DNA 161 polymerase (Thermo Fisher Scientific) using previously described custom barcoded primers (23). 
